Co-Founder Robert Ortenzio-Led Consortium to Take Select Medical Private for $3.9 Billion

Key Takeaways

• $3.9B take‑private deal values Select Medical at $16.5/share.
• Consortium includes co‑founder Ortenzio, Martin Jackson, and WCAS.
• Deal represents 10.55× EBITDA premium for the company.
• Debt remains unchanged; consortium leverages existing loan covenants.
• Closing expected mid‑2026 with JPMorgan and Wells Fargo financing.

Summary

Select Medical Holdings agreed to be taken private for $3.9 billion by a consortium led by co‑founder Robert Ortenzio, senior executive Martin Jackson, and private‑equity firm WCAS. The deal offers $16.5 in cash per share, a 10% premium to the prior close, and values the company at 10.55 times EBITDA. Existing debt will remain unchanged, with JPMorgan and Wells Fargo arranging the required financing. The transaction is slated to close in mid‑2026.

Pulse Analysis

Select Medical has built a nationwide network of critical‑illness recovery hospitals, inpatient rehab centers, and occupational health clinics, positioning it as a key player in the post‑acute care market. The company’s diversified service portfolio and steady cash flow make it attractive for private ownership, especially as the founder seeks to steer strategic initiatives that may be constrained by public‑market scrutiny. This backdrop aligns with a broader trend of healthcare operators consolidating to achieve scale, improve payer contracts, and invest in technology‑enabled care pathways.

The consortium’s structure blends founder insight with private‑equity capital, reflecting a hybrid approach to value creation. Valuing Select Medical at 10.55 times EBITDA and a 10% share‑price premium underscores confidence in its earnings stability and growth prospects. By keeping existing debt intact, the buyers can leverage established loan covenants, reducing refinancing risk and preserving liquidity for operational investments. WCAS brings deep sector expertise, while JPMorgan and Wells Fargo’s involvement as lead arrangers signals robust financing support for the $3.9 billion transaction.

For shareholders, employees, and patients, the deal promises a more agile governance model focused on long‑term care quality and expansion. Private ownership may accelerate initiatives such as tele‑rehabilitation, integrated occupational health services, and strategic acquisitions in underserved regions. Moreover, the mid‑2026 closing timeline gives the consortium ample runway to align regulatory approvals and integrate financing structures, setting a precedent for founder‑led take‑privates in the healthcare space.